





High pushability



Low profile and wide
range of sizes



Controlled
compliance




Technical data /
ordering info

Vascular Intervention // **Peripheral**
PTA Balloon Catheter/0.018"/OTW



 **BIOTRONIK**
excellence for life

Passeo-18



Highly pushable coaxial shaft design

A strong inner shaft and a flexible outer shaft creating a highly pushable and deliverable system.



Low profile and wide range of sizes


The available low profile 3.8F coaxial catheter shaft design facilitates access to distal lesions and allows reduction of access site complications.¹

Available balloon diameters/lengths

ø 2.0 - 5.0 mm



ø 6.0 mm - 7.0 mm



0 20 40 60 80 120 150 170 200


Balloon length (mm)

Controlled compliant balloon for predictable expansion

Low, controlled compliance for predictable radial balloon expansion to minimize the risk of dissection.

Patchwork coating for enhanced crossability


The penta-fold balloon is coated in a folded state, exposing uncoated balloon sections when inflated. This is intended to facilitate crossing while minimizing slippage during inflation.





Passeo-18

Vascular
Intervention
Peripheral



Indicated to dilate stenosis in the femoral, popliteal and infrapopliteal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

Technical Data	Balloon catheter
Catheter type	OTW
Recommended guide wire	0.018"
Tip	Short and tapered, colored
Balloon material	SCP (Semi-Crystalline Polymer), controlled compliance (4 - 8 %)
Balloon folding	5-fold
Balloon coating	Hydrophobic patchwork coating
Balloon markers	2 swaged markers (zero profile)
Sizes	ø 2.0 - 7.0 mm; L: 20 - 200 mm
Shaft	3.8F, 3.9F (ø 6.0 / 7.0 mm x 170 - 200 mm); coaxial design
Usable length	90, 130 and 150 cm

Compliance Chart	Balloon diameter x length (mm)							
	ø 2.0 x 20-170	ø 2.0 x 200	ø 2.5 x 20-170	ø 2.5 x 200	ø 3.0 x 20-170	ø 3.0 x 200	ø 3.5 x 20-170	ø 3.5 x 200
Nominal Pressure (NP)	atm* 6	6	6	6	6	6	6	6
	ø (mm) 2.0	2.0	2.5	2.5	3.0	3.0	3.5	3.5
Rated Burst Pressure (RBP)	atm* 15	14	15	14	15	14	15	14
	ø (mm) 2.1	2.1	2.6	2.6	3.2	3.2	3.7	3.7

Compliance Chart	Balloon diameter x length (mm)						
	ø 4.0 x 20-150	ø 4.0 x 170-200	ø 5.0 x 20-120	ø 5.0 x 150	ø 5.0 x 170-200	ø 6.0 x 20-200	ø 7.0 x 20-200
Nominal Pressure (NP)	atm* 6	6	6	6	6	6	6
	ø (mm) 4.0	4.0	5.0	5.0	5.0	6.0	7.0
Rated Burst Pressure (RBP)	atm* 15	13	15	12	13	12	12
	ø (mm) 4.3	4.2	5.3	5.2	5.2	6.2	7.3

*1 atm = 1.013 bar

Ordering Information	Catheter Length (cm)	Balloon ø (mm)	Balloon Length (mm)							
			20	40	60	80	120	150	170	200
4F Antegrade approach	90	2.0	366098	366099	366100	366104	366105	366106	366114	376276
	90	2.5	357451	357458	366101	357469	357476	366107	357483	376277
	90	3.0	357452	357459	366102	357470	357477	366108	357484	376278
	90	3.5	357453	357460	366103	357471	357478	366109	357485	376279
	90	4.0	357454	357461	357465	357472	357479	366110	376272	376280
	90	5.0	357455	357462	357466	357473	357480	366111	376273	376281
	90	6.0	357456	357463	357467	357474	357481	366112	376274	376282
	90	7.0	357457	357464	357468	357475	357482	366113 ^a	376275 ^a	376283 ^a

4F

Antegrade approach

5F

Ordering Information	Catheter Length (cm)	Balloon ø (mm)	Balloon Length (mm)							
			20	40	60	80	120	150	170	200
4F Retrograde approach	150	2.0	366115	366118	366119	366123	366126	366129	366137	376296
	130	2.5	357486	357491	366120	357502	357507	366130	357512	376297
	130	3.0	357487	357492	366121	357503	357508	366131	357513	376298
	130	3.5	357488	357493	366122	357504	357509	366132	357514	376299
	130	4.0	357489	357494	357498	357505	357510	366133	376292	376300
	130	5.0	357490	357495	357499	357506	357511	366134	376293	376301
	130	6.0	366116	357496	357500	366124	366127	366135	376294	376302
	130	7.0	366117	357497	357501	366125	366128	366136 ^a	376295 ^a	376303 ^a

4F

Retrograde approach

5F

^a8 weeks pre-order only

1. Bosiers M, Deloose K, Callaert J, et al. 4-French-compatible endovascular material is safe and effective in the treatment of femoropopliteal occlusive disease: results of the 4-EVER trial. J Endovasc Ther. 2013; 20: 746-756.

